- Home
- SLNO vs SWTX Comparison
SLNO vs SWTX Comparison
Compare SLNO & SWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLNO
- SWTX
- Stock Information
- Founded
- SLNO 1999
- SWTX 2017
- Country
- SLNO United States
- SWTX United States
- Employees
- SLNO N/A
- SWTX N/A
- Industry
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- SWTX Biotechnology: Pharmaceutical Preparations
- Sector
- SLNO Health Care
- SWTX Health Care
- Exchange
- SLNO Nasdaq
- SWTX Nasdaq
- Market Cap
- SLNO 3.2B
- SWTX 3.5B
- IPO Year
- SLNO 2014
- SWTX 2019
- Fundamental
- Price
- SLNO $73.35
- SWTX $46.71
- Analyst Decision
- SLNO Strong Buy
- SWTX Buy
- Analyst Count
- SLNO 9
- SWTX 7
- Target Price
- SLNO $103.33
- SWTX $56.86
- AVG Volume (30 Days)
- SLNO 744.8K
- SWTX 4.9M
- Earning Date
- SLNO 05-07-2025
- SWTX 05-09-2025
- Dividend Yield
- SLNO N/A
- SWTX N/A
- EPS Growth
- SLNO N/A
- SWTX N/A
- EPS
- SLNO N/A
- SWTX N/A
- Revenue
- SLNO N/A
- SWTX $219,670,000.00
- Revenue This Year
- SLNO N/A
- SWTX $79.29
- Revenue Next Year
- SLNO N/A
- SWTX $70.79
- P/E Ratio
- SLNO N/A
- SWTX N/A
- Revenue Growth
- SLNO N/A
- SWTX 730.42
- 52 Week Low
- SLNO $36.93
- SWTX $28.21
- 52 Week High
- SLNO $80.99
- SWTX $62.00
- Technical
- Relative Strength Index (RSI)
- SLNO 49.78
- SWTX 61.37
- Support Level
- SLNO $72.29
- SWTX $46.21
- Resistance Level
- SLNO $78.32
- SWTX $46.77
- Average True Range (ATR)
- SLNO 2.74
- SWTX 0.15
- MACD
- SLNO -0.57
- SWTX -0.04
- Stochastic Oscillator
- SLNO 27.11
- SWTX 91.67
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
About SWTX SpringWorks Therapeutics Inc.
SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.